1
|
Yost CC, Bhagat R, Blitzer D, Louis C, Han J, Wilder FG, Meguid RA. A primer for the student joining the general thoracic surgery service tomorrow: Primer 2 of 7. JTCVS OPEN 2023; 14:293-313. [PMID: 37425458 PMCID: PMC10328966 DOI: 10.1016/j.xjon.2023.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 04/02/2023] [Accepted: 04/08/2023] [Indexed: 07/11/2023]
Affiliation(s)
- Colin C. Yost
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pa
| | - Rohun Bhagat
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
| | - David Blitzer
- Division of Cardiovascular Surgery, Columbia University, New York, NY
| | - Clauden Louis
- Division of Cardiothoracic Surgery, Brigham and Women’s Hospital, Boston, Mass
| | - Jason Han
- Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, Pa
| | - Fatima G. Wilder
- Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass
| | - Robert A. Meguid
- Division of Cardiothoracic Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora, Colo
| |
Collapse
|
2
|
Fouladian P, Kohlhagen J, Arafat M, Afinjuomo F, Workman N, Abuhelwa AY, Song Y, Garg S, Blencowe A. Three-dimensional printed 5-fluorouracil eluting polyurethane stents for the treatment of oesophageal cancers. Biomater Sci 2020; 8:6625-6636. [DOI: 10.1039/d0bm01355b] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
3D printing is introduced as rapid and facile approach to prepare personalized drug-eluting stents for the treatment of oesophageal cancers.
Collapse
Affiliation(s)
- Paris Fouladian
- Pharmaceutical Innovation and Development (PIDG) Group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| | - Jarrod Kohlhagen
- Applied Chemistry and Translational Biomaterials (ACTB) group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| | - Mohammad Arafat
- Pharmaceutical Innovation and Development (PIDG) Group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| | - Franklin Afinjuomo
- Pharmaceutical Innovation and Development (PIDG) Group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| | - Nathan Workman
- Applied Chemistry and Translational Biomaterials (ACTB) group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| | - Ahmad Y. Abuhelwa
- Discipline of Clinical Pharmacology
- College of Medicine and Public Health
- Flinders University
- Bedford Park 5042
- Australia
| | - Yunmei Song
- Pharmaceutical Innovation and Development (PIDG) Group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| | - Sanjay Garg
- Pharmaceutical Innovation and Development (PIDG) Group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| | - Anton Blencowe
- Applied Chemistry and Translational Biomaterials (ACTB) group
- Clinical and Health Sciences
- University of South Australia
- Adelaide
- Australia
| |
Collapse
|
3
|
Sarfaty M, Lankry E, Moore A, Kurman N, Purim O, Kundel Y, Ben-Aharon I, Perl G, Ulitsky O, Gordon N, Sulkes A, Menasherov N, Kashtan H, Brenner B. Esophageal Cancer in Israel has Unique Clinico-Pathological Features: A Retrospective Study. J Cancer 2017; 8:2417-2423. [PMID: 28900478 PMCID: PMC5595070 DOI: 10.7150/jca.19210] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Accepted: 04/26/2017] [Indexed: 11/09/2022] Open
Abstract
Introduction: Data regarding esophageal cancer (EC) in Israel are limited. The aim of this study was hence to characterize this entity in the Israeli population and to compare it to the literature. Patients/Methods: This is a retrospective study of all consecutive EC patients treated at our institution between 1997-2013. Data were retrieved from patients' medical files. Results: Two hundred patients were included. The median age at diagnosis was 70.5 years; 63.5% were males; 63% were Ashkenazi Jews, 29% were Sephardic Jews, and 0.5% were Arabs. Squamous cell carcinoma (SCC) was predominant: 52% versus 45.5% with adenocarcinoma (ADC). SCC was common even in the distal esophagus (45%). The overall 5-year survival rate was 25.5%. A temporal trend (2006-2013 vs 1997-2005) shows a decline in the proportion of SCC (47% vs 63%, p=0.061) and a rise in ADC (50% vs 33%, p=0.041), with a parallel decrease in patients' age (median: 68.5 vs 73 years, p=0.014). In the later period, patients received more treatment for localized and metastatic disease, with a trend for improved median survival (20.1 vs 14.9 months, p=0.658). Ashkenazi Jews were diagnosed at an older age than Sephardic Jews (median: 73 vs. 65 years, p=0.001), had a higher rate of family history of GI cancer (34% vs. 17%, p=0.026) and a higher rate of cardiovascular co-morbidity (41% vs. 24%, p=0.041). Conclusion: EC in Israel represents an intermediate entity between the Western and the endemic subtypes, showing some unique features. These included delayed reversal of the SCC/ADC ratio, commonness of SCC in the distal esophagus, prevalence of other malignancies and predominance of Ashkenazi ethnicity. The reason for these findings is unclear and its further evaluation is warranted.
Collapse
Affiliation(s)
- Michal Sarfaty
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Esty Lankry
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Assaf Moore
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel
| | - Noga Kurman
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel
| | - Ofer Purim
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Yulia Kundel
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Irit Ben-Aharon
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Gali Perl
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Olga Ulitsky
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel
| | - Noa Gordon
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel
| | - Aaron Sulkes
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Nikolai Menasherov
- Department of Surgery A, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Hanoch Kashtan
- Department of Surgery B, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Baruch Brenner
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| |
Collapse
|
4
|
Tettey M, Edwin F, Aniteye E, Sereboe L, Tamatey M, Ofosu-Appiah E, Adzamli I. The changing epidemiology of esophageal cancer in sub-Saharan Africa - the case of Ghana. Pan Afr Med J 2012; 13:6. [PMID: 23308313 PMCID: PMC3527059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2012] [Accepted: 07/22/2012] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION Esophageal cancer portends a grim prognosis. Most patients present with incurable disease. Scanty epidemiologic data on the disease has contributed to its low priority on the national. We sought to evaluate the current national trend in the presentation and outcome of esophageal cancer using our institutional experience from 1992 - 2010. METHODS This is a retrospective study based on 152 patients who were seen in our institution during the study period. The perioperative data of these patients were retrieved and the relevant details recorded. Histopathological reports were available for 75 patients managed over the period. The study setting was The National Cardiothoracic Centre, which serves as the only tertiary referral centre in the country for cardiothoracic problems. RESULTS There were 122 males and 30 females with a mean age of 57.8 ± 11.7 years. The yearly trend from 1992 to 2010 showed a steady increase in the incidence of esophageal cancer. High alcohol consumption and smoking dominated the history of 82.2% of the patients. Squamous cell carcinoma accounted for 78.7% and adenocarcinoma 21.3%. Distribution of esophageal carcinoma by anatomical location was 84.9% for distal third, 11.8% for middle third and 3.3% for upper third. All patients presented with incurable disease. CONCLUSION The study shows an increasing incidence of esophageal carcinoma in this country. Alcohol abuse and smoking are major risk factors; squamous cell carcinoma is the dominant histological type in this study.
Collapse
Affiliation(s)
- Mark Tettey
- National Cardiothoracic Center, Box KB 846 Korle Bu Teaching Hospital, Accra, Ghana,Corresponding author: Mark Tettey, National Cardiothoracic Centre, Box K B 846, KBTH, Accra, Ghana
| | - Frank Edwin
- National Cardiothoracic Center, Box KB 846 Korle Bu Teaching Hospital, Accra, Ghana
| | - Ernest Aniteye
- National Cardiothoracic Center, Box KB 846 Korle Bu Teaching Hospital, Accra, Ghana
| | - Lawrence Sereboe
- National Cardiothoracic Center, Box KB 846 Korle Bu Teaching Hospital, Accra, Ghana
| | - Martin Tamatey
- National Cardiothoracic Center, Box KB 846 Korle Bu Teaching Hospital, Accra, Ghana
| | - Ernest Ofosu-Appiah
- National Cardiothoracic Center, Box KB 846 Korle Bu Teaching Hospital, Accra, Ghana
| | - Innocent Adzamli
- National Cardiothoracic Center, Box KB 846 Korle Bu Teaching Hospital, Accra, Ghana
| |
Collapse
|
5
|
Pinto CE, Fernandes DDS, Sá EAM, Telles WO, Jurandir Almeida D. Avaliação da reconstrução do trato alimentar com tubo gástrico ou colônico na esofagectomia por câncer de esôfago. Rev Col Bras Cir 2008. [DOI: 10.1590/s0100-69912008000600005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
OBJETIVO: Relatar a experiência com as principais técnicas de reconstrução do trato alimentar após esofagectomia por câncer de esôfago. METODOS: Foram analisados retrospectivamente 68 pacientes submetidos à esofagectomia entre fevereiro de 1997 e novembro de 2005. Todos os pacientes incluídos no estudo foram submetidos à esofagectomia com reconstrução com tubo gástrico ou colônico e anastomose cervical. RESULTADOS: A idade média foi de 55,4 anos (25-74 anos), 50 pacientes eram do sexo masculino e 18 pacientes do sexo feminino, 27 pacientes apresentavam o tumor localizado no esôfago médio e 41 pacientes no esôfago distal, sendo carcinoma epidermóide em 35 pacientes e adenocarcinoma em 33 pacientes. A ressecção foi por via transtorácica em 35 indivíduos e por via transhiatal em 33. A reconstrução com tubo gástrico se deu em 58 pacientes e com tubo colônico em 10 pacientes. A morbidade total da série foi de 52,9%. A mortalidade operatória foi de 5,8%. A sobrevida média foi de 35 meses. CONCLUSÃO: A esofagectomia com reconstrução com tubo gástrico e anastomose cervical é factível tecnicamente, sendo um procedimento realizado de rotina nos pacientes portadores de câncer de esôfago com indicação cirúrgica. Utilizamos, e recomendamos, a reconstrução com tubo colônico principalmente nos pacientes com cirurgia prévia no estômago ou quando da necessidade de ressecção ampliada deste, impossibilitando a confecção da reconstrução do trânsito alimentar com a gastroplastia.
Collapse
|